Recent News

• 08.03.2026 - Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• 06.30.2026 - Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
• 06.14.2026 - Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
• 06.14.2026 - Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
• 06.02.2026 - Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
• 06.02.2026 - Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
• 05.22.2026 - Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
• 05.07.2026 - Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
• 04.27.2026 - Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
• 04.08.2026 - Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Recent Filings

• 08.03.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 8-K Current report
• 08.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.03.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.31.2026 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 07.21.2026 - PREM14A Preliminary proxy statements relating to merger or acquisition
• 07.10.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.10.2026 - 8-K Current report
• 07.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - EX-99.1 EX-99.1